{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:18:46Z","timestamp":1788200326753,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.diabres.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T05:06:46Z","timestamp":1527311206000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control"],"prefix":"10.1016","volume":"142","author":[{"given":"Hyun Jeong","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Jeong","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Keun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2018.05.013_b0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1743-7075-2-29","article-title":"Prevalence, predisposition and prevention of type II diabetes","volume":"2","author":"Cheng","year":"2005","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.diabres.2018.05.013_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2362.32.s3.4.x","article-title":"Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes","volume":"32","author":"Greenberg","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabres.2018.05.013_b0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Uusitupa M; Finnish Diabetes Prevention Study. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2018.05.013_b0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm: 2017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2018.05.013_b0025","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2014.5951","article-title":"Insulin therapy for type 2 diabetes mellitus","volume":"311","author":"Wallia","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2018.05.013_b0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.pcd.2016.05.007","article-title":"Prevalence of unwillingness to use insulin therapy and its associated attitudes amongst patients with Type 2 diabetes in Saudi Arabia","volume":"10","author":"Batais","year":"2016","journal-title":"Prim Care Diabetes."},{"key":"10.1016\/j.diabres.2018.05.013_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/RMHP.S108586","article-title":"Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies","volume":"9","author":"Bell","year":"2016","journal-title":"Risk Manag Healthc Policy"},{"key":"10.1016\/j.diabres.2018.05.013_b0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.05.013_b0045","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/dom.12737","article-title":"Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin 0ver 52 weeks in patients with type 2 diabetes","volume":"18","author":"Mathieu","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2018.05.013_b0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdi.12453","article-title":"Efficacy and safety of dapagliflorzin in addition to insulin therapy in Japanese patients with type 2 diabetes.: Results of the interim analysis of 16-week double-blind treatment period","volume":"7","author":"Araki","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"14","key":"10.1016\/j.diabres.2018.05.013_b0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","article-title":"Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus","volume":"17","author":"Fioretto","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2018.05.013_b0060","doi-asserted-by":"crossref","unstructured":"Standards of Medical Care in Diabetes 2018. Diabetes Care 2018;41(Suppl. 1):S3","DOI":"10.2337\/dc18-Sppc01"},{"key":"10.1016\/j.diabres.2018.05.013_b0065","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(02)01276-7","article-title":"Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities","volume":"113","author":"LeRoith","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2018.05.013_b0070","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2648.2011.05853.x","article-title":"Psychological resistance to insulin therapy in adults with type 2 diabetes: mixed-method systematic review","volume":"68","author":"Wang","year":"2012","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.diabres.2018.05.013_b0075","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/dmrr.279","article-title":"Patient perceptions of diabetes and diabetes therapy: assessing quality of life","volume":"18","author":"Bradley","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2018.05.013_b0080","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/dme.12729","article-title":"Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES - Australia cross-sectional survey","volume":"32","author":"Holmes-Truscott","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2018.05.013_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11136-008-9419-1","article-title":"Psychological insulin resistance: patient beliefs and implications for diabetes management","volume":"18","author":"Brod","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.diabres.2018.05.013_b0090","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/1735-9066.185571","article-title":"Comparing the quality of life in insulin recipient and refusal patients with type 2 diabetes","volume":"21","author":"Khalili","year":"2016","journal-title":"Iran J Nurs Midwifery Res"},{"key":"10.1016\/j.diabres.2018.05.013_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2018.05.013_b0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bcpt.12457","article-title":"Diabetic ketoacidosis in a patient with Type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment","volume":"118","author":"Storgaard","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.diabres.2018.05.013_b0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diabet.2017.09.006","article-title":"Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes","volume":"44","author":"Min","year":"2018","journal-title":"Diabetes Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718302900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718302900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:54:15Z","timestamp":1558716855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822718302900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":21,"alternative-id":["S0168822718302900"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2018.05.013","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}